APOBEC3B [The Human Chemical-Genetic Interaction Map Project]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
======= APOBEC3B =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: APOBEC3B
  * **<color #00a2e8>Official Name</color>**: apolipoprotein B mRNA editing enzyme catalytic subunit 3B
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=9582|9582]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/Q9UH17|Q9UH17]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=APOBEC3B&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20APOBEC3B|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/607110|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**: N/A
  * **<color #00a2e8>UniProt Summary</color>**:  DNA deaminase (cytidine deaminase) which acts as an inhibitor of retrovirus replication and retrotransposon mobility via deaminase-dependent and -independent mechanisms. After the penetration of retroviral nucleocapsids into target cells of infection and the initiation of reverse transcription, it can induce the conversion of cytosine to uracil in the minus-sense single-strand viral DNA, leading to G-to-A hypermutations in the subsequent plus-strand viral DNA. The resultant detrimental levels of mutations in the proviral genome, along with a deamination- independent mechanism that works prior to the proviral integration, together exert efficient antiretroviral effects in infected target cells. Selectively targets single-stranded DNA and does not deaminate double-stranded DNA or single-or double- stranded RNA. Exhibits antiviral activity against simian immunodeficiency virus (SIV), hepatitis B virus (HBV) and human T- cell leukemia virus type 1 (HTLV-1) and may inhibit the mobility of LTR and non-LTR retrotransposons. {ECO:0000269|PubMed:12859895, ECO:0000269|PubMed:15466872, ECO:0000269|PubMed:16060832, ECO:0000269|PubMed:16527742, ECO:0000269|PubMed:20062055, ECO:0000269|PubMed:22457529}.

<button type='primary' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
|APOBEC C|
|APOBEC N|
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|deoxycytidine deaminase activity|
|cytidine deaminase activity|
|cytidine metabolic process|
|cytidine catabolic process|
|cytidine deamination|
|cytidine to uridine editing|
|pyrimidine ribonucleoside catabolic process|
|pyrimidine ribonucleoside metabolic process|
|DNA demethylation|
|base conversion or substitution editing|
|negative regulation of transposition|
|pyrimidine nucleoside catabolic process|
|regulation of transposition|
|ribonucleoside catabolic process|
|DNA dealkylation|
|nucleoside catabolic process|
|pyrimidine nucleoside metabolic process|
|pyrimidine-containing compound catabolic process|
|glycosyl compound catabolic process|
|nucleobase-containing small molecule catabolic process|
|demethylation|
|DNA methylation or demethylation|
|ribonucleoside metabolic process|
|DNA modification|
|pyrimidine-containing compound metabolic process|
|nucleoside metabolic process|
|glycosyl compound metabolic process|
|RNA modification|
|carbohydrate derivative catabolic process|
|defense response to virus|
|response to virus|
|nucleobase-containing compound catabolic process|
|heterocycle catabolic process|
|cellular nitrogen compound catabolic process|
|small molecule catabolic process|
|aromatic compound catabolic process|
|organic cyclic compound catabolic process|
|nucleobase-containing small molecule metabolic process|
|DNA metabolic process|
|innate immune response|
|zinc ion binding|
|defense response to other organism|
|carbohydrate derivative metabolic process|
|organonitrogen compound catabolic process|
|immune effector process|
|response to other organism|
|response to external biotic stimulus|
|response to biotic stimulus|
|defense response|
|RNA binding|
|RNA metabolic process|
|small molecule metabolic process|
|organic substance catabolic process|
|cellular catabolic process|
|immune response|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='default' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp47|Lapatinib 5μM R01 exp47]]|1.83|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
No correlation found to any other genes in chemogenomics.
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 0/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 16799
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 1.78 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='APOBEC3B Expression in NALM6 Cells: 1.78'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>